Showing results (311-320 of 356) with videos related to
Sort By:
Pageof 36
JAMA Cardiology|November 12, 2023
Decline in Estimated Glomerular Filtration Rate After Dapagliflozin in Heart Failure With Mildly Reduced or Preserved Ejection Fraction: A Prespecified Secondary Analysis of the DELIVER Randomized Clinical TrialFinnian R Mc Causland, Brian L Claggett, Muthiah Vaduganathan, et al.Journal of the American College of Cardiology|November 9, 2024
Effect of Finerenone on the KCCQ in Patients With HFmrEF/HFpEF: A Prespecified Analysis of FINEARTS-HFMingming Yang, Alasdair D Henderson, Atefeh Talebi, et al.Journal of Cardiac Failure|September 8, 2023
The Effect of Omecamtiv Mecarbil in Hospitalized Patients as Compared With Outpatients With HFrEF: An Analysis of GALACTIC-HFKieran F Docherty, John J V McMurray, Rafael Diaz, et al.International Journal of Infectious Diseases : IJID : Official Publication of the International Society for Infectious Diseases|April 15, 2026
Positive Predictive Value of Respiratory Infection Diagnoses in The Danish National Patient Registry: a Post-hoc Validation Analysis of the DANFLU-1 TrialJacob Christensen, Niklas Dyrby Johansen, Katrine Feldballe Bernholm, et al.European Journal of Heart Failure|January 4, 2023
Efficacy of omecamtiv mecarbil in heart failure with reduced ejection fraction according to N-terminal pro-B-type natriuretic peptide level: insights from the GALACTIC-HF trialKieran F Docherty, John J V McMurray, Brian L Claggett, et al.European Journal of Clinical Microbiology & Infectious Diseases : Official Publication of the European Society of Clinical Microbiology|January 29, 2026
Relative effectiveness of high-dose versus standard-dose influenza vaccine against hospitalizations and mortality according to Charlson Comorbidity Index: A post-hoc analysis of the DANFLU-1 randomized trialKatrine Feldballe Bernholm, Niklas Dyrby Johansen, Caroline Espersen, et al.JACC. Heart Failure|June 12, 2025
Efficacy and Safety of Finerenone in Heart Failure With Preserved Ejection Fraction: A FINE-HEART AnalysisJohn W Ostrominski, Gerasimos Filippatos, Brian L Claggett, et al.Diabetes Care|February 28, 2025
Efficacy and Safety of Finerenone in Type 2 Diabetes: A Pooled Analysis of Trials of Heart Failure and Chronic Kidney DiseaseJohn W Ostrominski, Brian L Claggett, Zi Michael Miao, et al.American Heart Journal|April 2, 2025
Rationale and design of NUDGE-CKD: A nationwide randomized factorial trial of electronic nudges for increasing guideline-directed medical therapy in chronic kidney diseaseKristoffer Grundtvig Skaarup, Niklas Dyrby Johansen, Lisbet Brandi, et al.Nature Medicine|August 27, 2022
Dapagliflozin across the range of ejection fraction in patients with heart failure: a patient-level, pooled meta-analysis of DAPA-HF and DELIVERPardeep S Jhund, Toru Kondo, Jawad H Butt, et al.Pageof 36